Vanguard Group Inc. Acquires 10,579 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Vanguard Group Inc. boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,735,998 shares of the company's stock after buying an additional 10,579 shares during the quarter. Vanguard Group Inc. owned approximately 2.03% of CRISPR Therapeutics worth $68,329,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the fourth quarter worth $39,000. Western Pacific Wealth Management LP lifted its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics during the third quarter worth $40,000. Spire Wealth Management increased its position in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after acquiring an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth approximately $80,000. Institutional investors and hedge funds own 69.20% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CRSP shares. Truist Financial increased their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective for the company in a report on Wednesday, February 12th. Barclays lifted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Royal Bank of Canada reduced their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $73.11.

CRISPR Therapeutics Stock Down 4.2 %

NASDAQ:CRSP traded down $1.64 during trading hours on Wednesday, reaching $37.31. The company had a trading volume of 292,948 shares, compared to its average volume of 1,626,774. The business's 50-day simple moving average is $41.04 and its two-hundred day simple moving average is $43.92. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -8.54 and a beta of 1.85. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 9,973 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the sale, the chief executive officer now owns 180,890 shares of the company's stock, valued at approximately $7,673,353.80. This trade represents a 5.23 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.